Pemetinib’s indications, mechanism of action, usage and dosage, side effects, drug interactions, etc.

1. Indications:

1.Pemetinib is a new treatment option for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma whose tumors detect FGFR2 gene fusions or other rearrangements detected by an FDA-approved test.

2.Pemetinib is also indicated for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) harboring FGFR1 rearrangements. These patients often suffer from relapse and refractory disease, and the emergence of pemetinib provides them with a new treatment approach.

2. Mechanism of action:

Pemetinib is unique in its potent and selective inhibition of FGFR subtypes1/2/3. It reduces cell viability by inhibiting the phosphorylation and signaling of FGFR, thereby effectively inhibiting the proliferation of tumor cells. At the same time, pemetinib can also inhibit the activity of tyrosine kinase, an enzyme that plays a key role in cell signal transduction. Its overactivation often leads to abnormal proliferation and invasion of tumor cells. Pemetinib binds to the ATP binding site of tyrosine kinase and blocks its activity, thereby inhibiting the growth and spread of tumor cells.

3. Medication methods and side effects:

For patients with biliary tract and cholangiocarcinoma, pemetinib is administered orally at 13.5mg per day for 14 days and then discontinued for 7 days, forming a 21 day treatment cycle. For patients with malignant bone marrow/lymphoma, it is recommended to take it orally once a day.13.5mg.

Although pemetinib is effective in treating cancer, patients may experience some side effects while using it. Common digestive side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which can often be relieved by adjusting your diet or taking anti-nausea medications. In addition, pemetinib may cause skin problems, eye problems, liver function abnormalities, and systemic symptoms. Therefore, while using pemetinib, patients should pay close attention to their physical condition and inform their doctors in time if they experience any discomfort.

4. Warnings and precautions:

1.Allergy warning: Patients who are allergic to pemetinib should use it with caution, and the patient's allergy history should be asked in detail before use.

2.Contraindicated for pregnant and lactating women: Pemetinib may cause harm to the fetus, so it is not recommended for women who are preparing to become pregnant or are already pregnant. At the same time, lactating women should not breastfeed while taking the medication and within one week after stopping the medication.

3.Dose adjustment: If adverse reactions occur, the dose can be appropriately reduced. For patients with severely impaired renal function, the recommended dose is 9 mg, once daily. Patients should not increase or decrease the dosage or stop taking the medicine on their own, and should strictly follow the doctor's instructions.

5. Drug interactions and medication use in special populations:

When using pemetinib, avoid concurrent use with strong or moderate CYP3A inhibitors to avoid increasing the risk of adverse reactions.

St. John's wort, grapefruit and their products may interact with pemetinib and affect the effect of the drug, so large amounts should be avoided while using pemetinib.

For special groups such as pregnant and lactating women and people with liver insufficiency, the risks and benefits should be carefully evaluated when using pemetinib, and individualized treatment should be carried out under the guidance of a doctor.